Business
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD.
About this update from Blue Water Ventures International, Inc.
[{"type":"text","content":"\n A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical creamPatients indicated their thought processes were clearer and more focused, and were more keenly aware of surroundings MIAMI, March 21, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. (\"Psycheceutical\" or the \"Company\") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the publication of pre-clinical observational data that supports the potential of its NeuroDirect™ ketamine topical cream as a treatment for PTSD. The study was published in the March 2023 issue of Drug Development & Delivery. The preliminary observational data indicates that the non-systemic topical cream could be more effective at treating PTSD symptoms than cur­rent ketamine treatment options, which utilize systemic delivery methods. Additionally, the study supports the Company’s belief that the topical cream approach would be more cost-effective than current ketamine therapy options. \"Administering ketamine with NeuroDirect drug delivery technology has shown observational promise in addressing undesirable side effects and providing therapeutic benefits,\" said Dr. Ronald Aung-Din, Clinical Advisor for Psycheceutical and inventor of the NeuroDirect™ delivery system. \"We believe this technology has the potential to play a significant role in developing new life-saving treatments for PTSD and other mental health conditions by safely dosing psychedelic compounds.\" Observational data was collected in a non-clinical setting from an outpa­tient Neurology and Neuropsychiatry prac­tice, examining 100 patients with intractable depression, anxiety, and other symptoms commonly associated with PTSD. Sub­jects were patients with long-term symptoms related to PTSD who had each tried numerous previous other treatments. The patient group was comprised of 61 females and 39 males, and the patients' ages ranged from 12 to 90 years. Objective measures like the Hamilton Depression Scale and EEG tracings documented the patients' responses. Family members and other observers also noted additional benefits from the treatment....